/
•
•
Detailed stories on technology startups, business and economic current affairs.
From making condoms to steering clear of costly formulations, the drugmaker’s strategy of taking the road less travelled could now give it a seat at the high table.

From making condoms to steering clear of costly formulations, the drugmaker’s strategy of taking the road less travelled could now give it a seat at the high table.

The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?
With a promoter who is unafraid to make bold bets and pivot to businesses holding more promise, investors can only look forward to better times.
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?
With a promoter who is unafraid to make bold bets and pivot to businesses holding more promise, investors can only look forward to better times.